Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;264(1):1-3.
doi: 10.1002/path.6323. Epub 2024 Jun 25.

Novel chemokine biomarkers in melanoma†

Alessio Giubellino  1   2 , Sara E Hamilton  1   2   3
Affiliations

Novel chemokine biomarkers in melanoma†

Alessio Giubellino et al. J Pathol. 2024 Sep.

Abstract

The melanoma tumor microenvironment is a complex milieu of cancer, inflammatory, and stromal cells. In this context, chemokines play a pivotal role in recruiting inflammatory cells and influence the tumor, exerting both pro-tumorigenic and anti-tumoral roles. Interactions between these cells is what ultimately hold together and transform the tumor into an efficient machine. A recent study found that chemokines CCL8, CCL15, and CCL20 were upregulated in melanoma cells when co-cultured with macrophages and were associated with poor survival rates. CCL8 and CCL15 also stimulated melanoma cell growth, invasion, and metastasis, and were highly expressed in tumors prone to metastasize, suggesting these chemokines are attractive and independent biomarkers. Understanding the intricated interactions within the tumor microenvironment could lead to prognostic biomarkers and to the development of new therapeutic strategies for melanoma. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Keywords: CCL15; CCL20; CCL8; chemokines; melanoma; tumor‐associated macrophages.

PubMed Disclaimer

References

    1. Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non‐response. Signal Transduct Target Ther 2022; 7: 331.
    1. Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity 2021; 54: 859–874.
    1. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers (Basel) 2020; 12: 1765.
    1. Xu M, Wang Y, Xia R, et al. Role of the CCL2‐CCR2 signalling axis in cancer: mechanisms and therapeutic targeting. Cell Prolif 2021; 54: e13115.
    1. Del Prete A, Salvi V, Soriani A, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 2023; 20: 432–447.

LinkOut - more resources